These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Glutaminase 1 plays critical roles in myelodysplastic syndrome and acute myeloid leukemia cells. Okabe S; Moriyama M; Arai Y; Gotoh A Cancer Biomark; 2024; 41(1):55-68. PubMed ID: 39213050 [TBL] [Abstract][Full Text] [Related]
8. Molecular targeting of glutaminase sensitizes ovarian cancer cells to chemotherapy. Masamha CP; LaFontaine P J Cell Biochem; 2018 Jul; 119(7):6136-6145. PubMed ID: 29633308 [TBL] [Abstract][Full Text] [Related]
9. Synergistic Effects of Glutamine Deprivation and Metformin in Acute Myeloid Leukemia. Liu TY; Fu X; Yang Y; Gu J; Xiao M; Li DJ Curr Med Sci; 2024 Aug; 44(4):799-808. PubMed ID: 39096478 [TBL] [Abstract][Full Text] [Related]
10. Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease. Soomro I; Sun Y; Li Z; Diggs L; Hatzivassiliou G; Thomas AG; Rais R; Parker SJ; Slusher BS; Kimmelman AC; Somlo S; Skolnik EY Nephrol Dial Transplant; 2018 Aug; 33(8):1343-1353. PubMed ID: 29420817 [TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Gross MI; Demo SD; Dennison JB; Chen L; Chernov-Rogan T; Goyal B; Janes JR; Laidig GJ; Lewis ER; Li J; Mackinnon AL; Parlati F; Rodriguez ML; Shwonek PJ; Sjogren EB; Stanton TF; Wang T; Yang J; Zhao F; Bennett MK Mol Cancer Ther; 2014 Apr; 13(4):890-901. PubMed ID: 24523301 [TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of a novel glutaminase inhibitor. Cederkvist H; Kolan SS; Wik JA; Sener Z; Skålhegg BS FEBS Open Bio; 2022 Jan; 12(1):163-174. PubMed ID: 34698439 [TBL] [Abstract][Full Text] [Related]
13. Glutaminase-1 stimulates the proliferation, migration, and survival of human endothelial cells. Peyton KJ; Liu XM; Yu Y; Yates B; Behnammanesh G; Durante W Biochem Pharmacol; 2018 Oct; 156():204-214. PubMed ID: 30144404 [TBL] [Abstract][Full Text] [Related]
14. Glutaminase 1 regulates the release of extracellular vesicles during neuroinflammation through key metabolic intermediate alpha-ketoglutarate. Wu B; Liu J; Zhao R; Li Y; Peer J; Braun AL; Zhao L; Wang Y; Tong Z; Huang Y; Zheng JC J Neuroinflammation; 2018 Mar; 15(1):79. PubMed ID: 29540215 [TBL] [Abstract][Full Text] [Related]
15. Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). Robinson MM; McBryant SJ; Tsukamoto T; Rojas C; Ferraris DV; Hamilton SK; Hansen JC; Curthoys NP Biochem J; 2007 Sep; 406(3):407-14. PubMed ID: 17581113 [TBL] [Abstract][Full Text] [Related]
17. The activation loop and substrate-binding cleft of glutaminase C are allosterically coupled. Li Y; Ramachandran S; Nguyen TT; Stalnecker CA; Cerione RA; Erickson JW J Biol Chem; 2020 Jan; 295(5):1328-1337. PubMed ID: 31871054 [TBL] [Abstract][Full Text] [Related]
18. Conformational changes in the activation loop of mitochondrial glutaminase C: A direct fluorescence readout that distinguishes the binding of allosteric inhibitors from activators. Stalnecker CA; Erickson JW; Cerione RA J Biol Chem; 2017 Apr; 292(15):6095-6107. PubMed ID: 28196863 [TBL] [Abstract][Full Text] [Related]
19. Targeting glutamine metabolism slows soft tissue sarcoma growth. Lee P; Malik D; Perkons N; Huangyang P; Khare S; Rhoades S; Gong YY; Burrows M; Finan JM; Nissim I; Gade TPF; Weljie AM; Simon MC Nat Commun; 2020 Jan; 11(1):498. PubMed ID: 31980651 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. Shukla K; Ferraris DV; Thomas AG; Stathis M; Duvall B; Delahanty G; Alt J; Rais R; Rojas C; Gao P; Xiang Y; Dang CV; Slusher BS; Tsukamoto T J Med Chem; 2012 Dec; 55(23):10551-63. PubMed ID: 23151085 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]